Rivian (NASDAQ: RIVN) hit the public markets last week. A company with only a few dozen vehicle sales and a market cap over $100 billion seems to have broken the imagination of some investors. It's hard to see how to justify Rivian's valuation given its current production of only a few hundred vehicles, but the market is a forward- looking mechanism, so we need to think about what Rivian will look like in the future. The company's first manufacturing plant in Normal, Illinois, has a stated capacity of 150,000 with the potential to increase to 200,000 vehicles by 2023 with some upgrades. Read More...
Motley Fool
1 Cancer Stock on Buyout Watch in 2022
The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines. Third, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer, and Sanofi are all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios.
